Search results
Showing 1 to 9 of 9 results for faricimab
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]
In development [GID-TA11193] Expected publication date: 04 December 2024
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.